During the recent national webinar and congressional briefing, “PRGLAC Then and Now: Where We Are and Where We’re Going,” the last of a three-part congressional briefing series hosted by the Coalition to Advance Maternal Therapeutics (CAMT), invited representatives from key federal agencies to discuss how they were working to advance Read more…
Experts agree that leaving pregnant and lactating populations out of clinical trials can cause harm and create uncertainty for both mother and baby. During the national webinar and congressional briefing, “Pregnant and Lactating Populations in Research: How Leaving These Populations Out Leaves Them Behind,” part two of a three-part series Read more…
While Congress and the Administration had several priorities toward the end of the 117th Congress, including passing an end-of-year spending package for fiscal year 2023, the Coalition to Advance Maternal Therapeutics (CAMT) was successful in its efforts to help drive policy toward greater inclusion of pregnant and lactating populations in Read more…
Including pregnant and lactating populations in research is critical to gaining a greater understanding of the safety and efficacy of medications on these populations and improve outcomes for both mother and baby. However, women of childbearing age have historically been excluded from clinical trials. In 1977, as a result of Read more…
Representatives Castor, Fitzpatrick, and Underwood on December 13, 2022 introduced H.R. 9487, the Advancing Safe Medications for Moms and Babies Act of 2022.